Table 1

Baseline characteristics and total COVID-19 vaccine exposure (before and during study)

Baseline characteristics, number of participants, n (% of total)*Total vaccines received by end of follow-up, number of participants, n (% of category)*
ChAdOx1BNT162b2Other†
One dose onlyTwo dosesOne dose onlyTwo dosesAny doses
Overall11 475 (100)331 (2.9)5497 (47.9)270 (2.4)4240 (36.9)1137 (9.9)
Sex
 Male4609 (40.2)135 (2.9)2351 (51.0)94 (2.0)1574 (34.2)455 (9.9)
 Female6855 (59.7)196 (2.9)3141 (45.8)176 (2.6)2661 (38.8)681 (9.9)
Age (years)
 18–391788 (15.6)18 (1.0)280 (15.7)107 (6.0)1109 (62.0)274 (15.3)
 4–-644661 (40.6)176 (3.8)2811 (60.3)68 (1.5)1170 (25.1)436 (9.4)
 65+5023 (43.8)137 (2.7)2406 (47.9)95 (1.9)1959 (39)426 (8.5)
BMI (kg/m2)
 <18.5163 (1.4)5 (3.1)82 (50.3)<561 (37.4)13 (8.0)
 18.5–<253780 (32.9)84 (2.2)1795 (47.5)96 (2.5)1492 (39.5)313 (8.3)
 25–<303728 (32.5)83 (2.2)1906 (51.1)71 (1.9)1352 (36.3)316 (8.5)
 30–<402441 (21.3)75 (3.1)1155 (47.3)57 (2.3)914 (37.4)240 (9.8)
 40+518 (4.5)14 (2.7)260 (50.2)10 (1.9)197 (38.0)37 (7.1)
Ethnicity
 Other275 (2.4)13 (4.7)103 (37.5)11 (4.0)120 (43.6)28 (10.2)
 White11 200 (97.6)318 (2.8)5394 (48.2)259 (2.3)4120 (36.8)1109 (9.9)
Occupational status
 Unemployed524 (4.6)20 (3.8)214 (40.8)18 (3.4)203 (38.7)69 (13.2)
 Employed5053 (44.0)146 (2.9)2103 (41.6)159 (3.1)2038 (40.3)607 (12.0)
 Retired5898 (51.4)165 (2.8)3180 (53.9)93 (1.6)1999 (33.9)461 (7.8)
Currently smoke
 No10 189 (88.8)245 (2.4)4999 (49.1)223 (2.2)3844 (37.7)878 (8.6)
 Yes441 (3.8)16 (3.6)199 (45.1)13 (2.9)172 (39.0)41 (9.3)
No. of comorbidities
 None3548 (30.9)133 (3.7)1496 (42.2)126 (3.6)1312 (37.0)481 (13.6)
 12867 (25.0)67 (2.3)1463 (51.0)56 (2.0)1057 (36.9)224 (7.8)
 22253 (19.6)58 (2.6)1109 (49.2)36 (1.6)856 (38.0)194 (8.6)
 3+2807 (24.5)73 (2.6)1429 (50.9)52 (1.9)1015 (36.2)238 (8.5)
Advised to shield
 Yes960 (8.4)32 (3.3)506 (52.7)21 (2.2)293 (30.5)108 (11.2)
 No9600 (83.7)225 (2.3)4660 (48.5)213 (2.2)3702 (38.6)800 (8.3)
Had COVID before study entry
 Yes1256 (10.9)40 (3.2)544 (43.3)33 (2.6)504 (40.1)135 (10.7)
 No9304 (81.1)217 (2.3)4622 (49.7)201 (2.2)3491 (37.5)773 (8.3)
  • *Subgroups may not sum to the total because unknowns are omitted.

  • †Includes participants who received both ChAdOx1 and BNT162b2 and any who reported other COVID-19 vaccines alone or in combination with ChAdOx1 or BNT162b2.

  • BMI, body mass index.